A Study of ALT-803 in Patients With Relapsed or Refractory Multiple Myeloma

This trial is active but is no longer accepting patients.

Trial Overview

This is a Phase Ib/II, open-label, multi-center, competitive enrollment and dose escalation study of ALT-803 in patients with relapsed or refractory multiple myeloma.


What is the phase of this trial?

Phase 1/2 what does this mean

What type of trial is this?

This is an interventional trial. This type of trial actively treats your myeloma.

What treatments are used in this trial?
How many patients will participate in this trial?

Approximately 50 patients will be enrolled in this study.

Who is sponsoring this trial?

Altor Bioscience Corporation

SparkCures Trial Identifiers

MM-0509 , NCT02099539 what is this

Am I Eligible For This Trial?

All clinical trials provide reasons that patients may or may not be able to join called 'eligibility criteria'. The following is a high-level eligibility criteria provided by the sponsor of this trial. Additional eligibility criteria may apply.

Trial Contact Information

There are no active locations for this trial.